Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions

Eugène van Puijenbroek, Andrew Bate, Hubert G.M. Leufkens et al. · Pharmacoepidemiology and Drug Safety · 2002 · 1.3K citations

Pharmacy, Pharmacology, Clinical Pharmacology +16

Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists

Robert S. Wallis, Michael S. Broder, Jia Yi Karen Wong et al. · Clinical Infectious Diseases · 2004 · 978 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +10

Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union

Thijs J. Giezen, Aukje K. Mantel‐Teeuwisse, Sabine M. J. M. Straus et al. · JAMA · 2008 · 268 citations

Pharmacy, Pharmaceutical Policy, Immunization +16

Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases

Fleur Grégoire, Annie Fourrier‐Réglat, Françoise Haramburu et al. · Drug Safety · 2007 · 245 citations

Health Professions, Risk Management, Patient Safety +12

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

Ronald van Vollenhoven, Roy Fleischmann, Daniel E. Fürst et al. · The Journal of Rheumatology · 2015 · 239 citations · Full text

Life Sciences, Immunology, Internal Medicine +17